These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 6230609)

  • 1. [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up].
    Chicaud P; Demange J; Drouin P; Debry G
    Presse Med; 1984 Feb; 13(7):417-9. PubMed ID: 6230609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the concanavalin A precipitation technique in an evaluation of fenofibrate action on cholesterolemia in IIa and IIb hyperlipemic subjects.
    Chicaud P; Demange J; Drouin P; Debry G
    Pharmacology; 1983; 26(2):90-4. PubMed ID: 6844393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypercholesterolaemia with fenofibrate: a review.
    Brown WV
    Curr Med Res Opin; 1989; 11(5):321-30. PubMed ID: 2649318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of combined hyperlipidaemia and its treatment with fenofibrate.
    Superko HR
    J Int Med Res; 1989; 17(2):99-112. PubMed ID: 2656334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
    Fricker J; Douste-Blazy P; Drouin P; De Gennes JL; Dachet C; Keller U
    Presse Med; 1990 Dec; 19(42):1927-30. PubMed ID: 2147752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
    Schneider A; Stange EF; Ditschuneit HH; Ditschuneit H
    Atherosclerosis; 1985 Sep; 56(3):257-62. PubMed ID: 4052147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
    Steinmetz J; Morin C; Panek E; Siest G; Drouin P
    Clin Chim Acta; 1981 Apr; 112(1):43=53. PubMed ID: 6113065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia.
    Oztürk LK; Yarat A; Emekli N
    Arzneimittelforschung; 2007; 57(12):770-6. PubMed ID: 18380409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quantitative coronary angiography: progression and regression of coronary stenoses--an intervention study with fenofibrate].
    Hahmann HW; Bunte T; Hellwig N; Hau U; Becker D; Dyckmans J; Keller HE; Schieffer HJ
    Z Kardiol; 1991 Oct; 80(10):589-94. PubMed ID: 1771957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?].
    Leschke M; Höffken H; Schmidtsdorff A; Blanke H; Egbring R; Joseph K; Strauer BE
    Dtsch Med Wochenschr; 1989 Jun; 114(24):939-44. PubMed ID: 2731478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of European clinical experience with fenofibrate.
    Blane GF
    Cardiology; 1989; 76 Suppl 1():1-10; discussion 10-3. PubMed ID: 2653620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
    Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J
    Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate.
    Plancke MO; Olivier P; Clavey V; Marzin D; Fruchart JC
    Methods Find Exp Clin Pharmacol; 1988 Sep; 10(9):575-9. PubMed ID: 3226223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.